Arrowstreet Capital Limited Partnership Acquires 361,539 Shares of Hologic, Inc. (NASDAQ:HOLX)

Arrowstreet Capital Limited Partnership grew its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 27.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,687,347 shares of the medical equipment provider’s stock after buying an additional 361,539 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Hologic were worth $121,641,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp raised its holdings in Hologic by 0.8% in the 3rd quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after purchasing an additional 81,057 shares in the last quarter. Victory Capital Management Inc. raised its stake in Hologic by 0.5% in the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock worth $354,506,000 after buying an additional 24,358 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Hologic by 3.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider’s stock worth $322,272,000 after buying an additional 129,035 shares during the period. Boston Partners boosted its position in Hologic by 81.0% during the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after acquiring an additional 1,602,463 shares in the last quarter. Finally, Nordea Investment Management AB grew its holdings in shares of Hologic by 32.7% during the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after acquiring an additional 544,889 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on HOLX shares. Wolfe Research assumed coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. Needham & Company LLC cut shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a report on Monday, February 3rd. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. BNP Paribas raised shares of Hologic to a “strong-buy” rating in a research note on Tuesday, December 10th. Finally, Morgan Stanley decreased their target price on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Eleven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $84.62.

Hologic Trading Down 1.6 %

Shares of NASDAQ:HOLX opened at $61.32 on Monday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic, Inc. has a 1 year low of $60.34 and a 1 year high of $84.67. The company has a market cap of $13.76 billion, a P/E ratio of 19.34, a PEG ratio of 2.14 and a beta of 0.97. The stock’s fifty day moving average price is $65.24 and its 200-day moving average price is $73.24.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.